Literature DB >> 10815917

Flow cytometric analysis of androgen receptor expression in human prostate tumors and benign tissues.

A Krishan1, A Oppenheimer, W You, R Dubbin, D Sharma, B L Lokeshwar.   

Abstract

Androgen receptor (AR) plays an important role in growth and hormonal therapy of human prostate tumors. Immunohistochemical analysis of AR expression, a nonquantitative technique, is currently used for screening of receptor expression in prostate tissues. The present report describes a laser flow cytometric method for monitoring AR expression in human cell lines and in archival formalin-fixed paraffin-embedded prostate tissues and tumors. Multiparametric flow analysis can be used for simultaneous detection of other cellular markers (e.g., DNA aneuploidy), and by gated analysis, AR expression in subpopulations of a tumor can be quantitatively determined.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10815917

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  3 in total

1.  Androgen receptor as a licensing factor for DNA replication in androgen-sensitive prostate cancer cells.

Authors:  Ivan V Litvinov; Donald J Vander Griend; Lizamma Antony; Susan Dalrymple; Angelo M De Marzo; Charles G Drake; John T Isaacs
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-02       Impact factor: 11.205

2.  Cystatin C is downregulated in prostate cancer and modulates invasion of prostate cancer cells via MAPK/Erk and androgen receptor pathways.

Authors:  Barbara Wegiel; Thomas Jiborn; Magnus Abrahamson; Leszek Helczynski; Leo Otterbein; Jenny Liao Persson; Anders Bjartell
Journal:  PLoS One       Date:  2009-11-23       Impact factor: 3.240

3.  Multiple cellular mechanisms related to cyclin A1 in prostate cancer invasion and metastasis.

Authors:  Barbara Wegiel; Anders Bjartell; Johanna Tuomela; Nishtman Dizeyi; Martina Tinzl; Leszek Helczynski; Elise Nilsson; Leo E Otterbein; Pirkko Härkönen; Jenny Liao Persson
Journal:  J Natl Cancer Inst       Date:  2008-07-08       Impact factor: 13.506

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.